Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS) (NCT03552263) | Clinical Trial Compass
CompletedPhase 2
Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)
United States132 participantsStarted 2018-06-07
Plain-language summary
Acute mountain sickness (AMS) is one of three syndromes of altitude illness. It is very common when people venture over 2500 meters altitude. This illness is mainly induced by acute exposure to low partial pressure of oxygen at high altitude that will cause a pathological effect on humans. T89 capsule is a modernized industrialized traditional Chinese herbal medicine. It is a botanical drug for oral use. In recent years, several literatures and clinical studies have showed that oral administration of T89 may provide substantial benefits in the prevention or alleviation of symptoms associated with acute mountain sickness (AMS), including nausea, vomiting, headache, dizziness, fatigue, and sleep disturbance. Such effect was also observed in a pilot clinical study recently conducted in Tibet in China.
This study is a prospective, double-blind, randomized, placebo-controlled phase 2 clinical trial having three arms including T89 low-dose, T89 high-dose and a placebo controlled group. People will be screened against the inclusion/exclusion criteria after informed consent signed. Eligible subjects will be randomly assigned into one of three arms and instructed to use T89 orally twice daily for 14 days (Days 1-14) before ascending, and 5 days after ascending during the observation period (Days 15-19). The primary efficacy parameter is Lake Louise Scoring System (LLSS) which will be evaluated by subject-self and principal investigator in clinic.
Who can participate
Age range18 Years – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Healthy volunteers: ages 18 - 55 years old;
✓. Primary residence elevation of 1,000 ft or lower;
✓. Not ascending to altitude \>10,000 ft within 4 months prior to screening;
✓. Females of childbearing potential must have a negative pregnancy test, not be breast feeding and established on a method of contraception that in the investigator's opinion is acceptable. Females must agree to remain on their established method of contraception from the time of the screening visit and throughout the study period.
✓. Willing to participate voluntarily and to sign a written informed consent.
Exclusion criteria
✕. Subjects with medical history of cardiovascular, cerebrovascular diseases or asthma;
✕. Subjects with clinically significant respiratory system disease, digestive disease, mental disease, metabolic disease, acute infection or anemia;
✕. Total LLSS self-assessment score and clinical assessment score is greater than 1 before ascending (Screening visit and Visit 1);
What they're measuring
1
The LLSS self- and clinical assessments score on Day 16 morning(next morning of arrival at high altitude) between T89 and Placebo groups.
Timeframe: Day 16 morning (next morning of arrival at high altitude)
✕. Blood oxygen saturation (SpO2) \<95% at sea level;
✕. Subjects with abnormal renal or liver function with clinical significance (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2×upper limits of normal(ULN), Creatinine\> ULN);
✕. Subjects with C reactive protein (CRP) \> ULN;
✕. Subjects with primary headache;
✕. Surgery or blood donation within 3 months prior to screening;